Monoclonal antibody · developed by Upstream Bio
Verekitug (UPB-101, ASP-7266) is a subcutaneously injected agent studied in severe asthma, asthma, and chronic rhinosinusitis with nasal polyps.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06966479 | Phase 2 | Severe Asthma | Active not recruiting | UPB |
| NCT06164704 | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | Completed | UPB |
| NCT05448651 | Phase 1 | Asthma | Completed | UPB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Severe AsthmaAsthmaChronic Rhinosinusitis With Nasal Polyps
Updated Nov 1, 2026. Something wrong or missing? Report it on the UPB page.
See UPB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
UPB catalysts and pipeline →